---

Intra-tympanic Gentamicin Therapy — Comprehensive 50-Mark Answer

---

1. INTRODUCTION & HISTORICAL BACKGROUND

---

2. INDICATIONS

Primary Indication

• Disabling vertigo not controlled by conservative medical therapy (low-salt diet, diuretics, betahistine, vestibular suppressants) for ≥6 months
• Serviceable or poor hearing in the affected ear
• Failure of endolymphatic sac surgery or Meniett device therapy

Secondary/Other Indications

• Chemical labyrinthectomy as an alternative to surgical labyrinthectomy in patients unfit for surgery
• Failed endolymphatic sac decompression
• Bilateral Ménière's disease (with caution)
• Recurrent vertigo after previous IT treatment

Contraindications

• Only-hearing ear (relative — risk of profound sensorineural hearing loss)
• Active chronic otitis media / tympanic membrane perforation (relative)
• Known mitochondrial A1555G mutation (increased ototoxic susceptibility)
• Contralateral vestibular dysfunction (higher risk of permanent bilateral disequilibrium)
• Uncontrolled diabetes, renal failure (systemic absorption risk)

---

3. ANATOMY & ROUTE OF DRUG DELIVERY

Route: Transtympanic → Middle Ear → Round Window Membrane (RWM) → Perilymph

                    TYMPANIC MEMBRANE
                         |
                    [Injection site]
                    Antero-inferior
                    quadrant (AT)
                    or via myringotomy
                         |
                    MIDDLE EAR CAVITY
                         |
               ┌─────────┴──────────┐
               ↓                    ↓
         ROUND WINDOW           OVAL WINDOW
         MEMBRANE               (less important
         (primary route)         route)
               |
               ↓
         PERILYMPH (scala tympani)
               |
               ↓
         INNER EAR HAIR CELLS
         (Vestibular >> Cochlear)
               |
               ↓
         VESTIBULAR DARK CELLS

---

4. MECHANISM OF ACTION

4A. Pharmacological Mechanism

• Gentamicin enters hair cells via mechanotransduction channels (MET channels)
• Generates reactive oxygen species (ROS) → activates caspase pathways → apoptosis
• Type I vestibular hair cells are more rapidly and severely damaged than Type II
• Type II hair cells may partially regenerate (~55% in animal models); Type I show NO regeneration
• This differential damage forms the basis of partial vestibular ablation

• Vestibular dark cells maintain ionic homeostasis of the endolymph
• Aminoglycosides structurally and functionally alter dark cells
• This disturbs ion homeostasis → opposes the ionic dysregulation of endolymphatic hydrops
• May restore ionic balance without necessarily destroying hair cells
• Caveat: No firm scientific evidence; one study found dark cell damage secondary to, not preceding, hair cell damage — Cummings

• Rapid high-dose perfusion → necrotic hair cell death pattern
• Slow/chronic perfusion → apoptotic pattern (clinically preferred — less cochlear damage)

4B. Clinical Effect

"Overwhelming clinical evidence suggests that vestibular ablation is not required for vertigo control. These observations have caused a shift in strategy from vestibular ablation to chemical alteration or subablation." — Cummings Otolaryngology

• Reduces the critical threshold of abnormal endolymphatic membrane ruptures that trigger hydrops attacks
• Dampens aberrant afferent signals from the affected labyrinth
• Promotes central compensation over time

---

5. PHARMACOKINETICS

• IT injection follows a one-compartment pharmacokinetic model in perilymph
• Gentamicin is rapidly eliminated from perilymph but has significant uptake into inner ear tissues (second, deeper compartment) — explains delayed toxicity
• Detected in serum 1–2 hours after IT administration → crosses blood-labyrinth barrier
• RWM exposure duration and drug concentration both determine functional/morphologic outcome
• Computer simulations show drug spreads from RWM to vestibule via scala rather than across the helicotrema

---

6. TREATMENT PROTOCOLS

FLOWCHART: IT Gentamicin Protocol Selection

                   PATIENT WITH INTRACTABLE
                    MÉNIÈRE'S DISEASE
                           |
              ┌────────────┼─────────────┐
              ↓            ↓             ↓
         FIXED          TITRATED    SUSTAINED-RELEASE
        PROTOCOL        PROTOCOL       PROTOCOL
     ("Shotgun")                     (Microcatheter/
                                      Hydrogel/Wick)

---

6A. Fixed (Shotgun) Protocol — Nedzelski et al. (1992)

• Gentamicin 26.7 mg/mL (40 mg/mL adjusted to pH 6.4 with NaHCO₃)
• 4 consecutive daily injections into the middle ear
• 0.5 mL per injection
• Patient recumbent, head tilted 45° toward treated ear for 30 minutes post-injection
• Advantages: standardized, reproducible, cost-effective
• Disadvantage: HL rate 25–30%, significant ablation
• Largest long-term series: >90 patients over a decade

6B. Titration Protocol (Low-Dose, Preferred)

• Concentration: 26.7–40 mg/mL
• Frequency: Once weekly (most common) or once monthly
• Injections are repeated until a titration endpoint is reached:
  • Appearance of paralytic nystagmus
  • Decreased tandem gait
  • Subjective disequilibrium
  • Control of vertigo attacks
• Most recent studies use 2–4 weekly injections
• Significantly lower HL rate: 0–3.5% substantial HL
• Preferred in patients with serviceable hearing

6C. Sustained-Release Protocol

• Uses delivery vehicles to maintain prolonged RWM contact:
  • Microcatheters (1 µL/hour for 10 days — Hoffer protocol)
  • Microwicks (placed through myringotomy tube)
  • Fibrin-based gentamicin-impregnated glue
  • Hydrogels (e.g., poloxamer 407)
  • Pledgets soaked in gentamicin solution
• More controlled, predictable kinetics
• Expensive; technically demanding

6D. Table of Selected IT Gentamicin Protocols (Cummings Table 158.4)

---

7. INJECTION TECHNIQUE

STEP-BY-STEP PROCEDURE

STEP 1: PATIENT PREPARATION
│  ├─ Informed consent (risk of hearing loss, tinnitus, disequilibrium)
│  ├─ Audiogram + vestibular function tests (caloric, VEMP)
│  └─ Topical anaesthetic (EMLA cream / phenol to TM × 10 min)

STEP 2: DRUG PREPARATION
│  ├─ Gentamicin 40 mg/mL (standard IV formulation)
│  ├─ Buffered with sodium bicarbonate → pH 6.4–7.4
│  ├─ 0.3–0.5 mL drawn in tuberculin syringe
│  └─ 25–27 gauge spinal needle (bent at 90°)

STEP 3: INJECTION
│  ├─ Patient supine, head turned 30–45° away from treated ear
│  ├─ Otoscopic visualization
│  ├─ Needle through postero-superior quadrant of TM (or via existing grommet)
│  ├─ Inject slowly; air vent via second puncture in TM if needed
│  └─ 0.4–0.5 mL injected to fill middle ear

STEP 4: POST-INJECTION POSITIONING
│  ├─ Patient remains supine × 30 minutes
│  ├─ Head tilted toward treated ear (round window down)
│  └─ No swallowing, nose blowing for 30 minutes

STEP 5: MONITORING
   ├─ Audiogram 1 week after each injection
   ├─ Vestibular assessment (head thrust test, caloric)
   └─ Symptom diary (vertigo frequency/severity)

Injection Site

• Classic site: Postero-inferior quadrant (avoids ossicular chain)
• Alternative: Antero-inferior quadrant with needle directed toward promontory
• The round window niche is in the infero-posterior middle ear — patient positioning maximizes drug contact with the RWM

---

8. ASSESSMENT OF OUTCOMES

AAO-HNS 1995 Guidelines for Ménière's Disease

• Vertigo control (Class A/B): 80–90% of patients
• Complete vertigo abolition (Class A): 50–75% with titration protocols
• HL (>10 dB PTA): 0–30% (protocol-dependent)

---

9. COMPLICATIONS

9A. Hearing Loss (Most Important)

• Most notorious complication
• Rate varies widely: 0–3.5% (titration) to 25–35% (shotgun)
• Risk factors:
  • Poor pre-treatment hearing
  • Mitochondrial 12S rRNA A1555G mutation (maternally inherited genetic susceptibility)
  • High-dose, high-frequency protocols
  • Rapid necrotic pattern of hair cell death
• If severe HL occurs, it usually manifests within 24 hours of injection
• 80% of HL cases apparent at 1 month; those without HL at 1 month → 92% stable at 2 years

9B. Acute Vestibular Deafferentation Syndrome ("Chemical Labyrinthine Upset")

• Expected, transient outcome
• Onset: 3–5 days after injection
• Symptoms: Vertigo, nausea, oscillopsia, disequilibrium
• Distinguishable from Ménière's attack: progressively worsens until peak at ~1 week (vs. Ménière attacks that self-resolve)
• Peak symptoms last 2–3 days
• Resolution in 2–4 weeks with vestibular rehabilitation
• Management: Vestibular rehabilitation exercises; discourage strict bedrest to promote central compensation

9C. Other Complications

• Persistent tympanic membrane perforation (uncommon with careful technique)
• Otitis media (secondary to perforation or grommet)
• Tinnitus exacerbation (transient)
• Permanent disequilibrium — higher risk in:
  • Pre-existing contralateral vestibular deficit
  • Peripheral neuropathy
  • History of stroke
  • Postural/motor deficits
  • Visual impairment
  • Advanced age
• Visual-vestibular mismatch syndrome — poorly coordinated visual and vestibular input, manifesting as motion sickness/dizziness with visual stimulation

---

10. COMPARISON WITH OTHER TREATMENTS FOR INTRACTABLE MÉNIÈRE'S DISEASE

FLOWCHART: Management of Intractable Ménière's Disease

                MÉNIÈRE'S DISEASE WITH DISABLING VERTIGO
                              │
                              ↓
               STEP 1: CONSERVATIVE MEDICAL THERAPY
               • Low-salt diet (<1.5 g/day)
               • Diuretics (hydrochlorothiazide/triamterene)
               • Betahistine, vestibular suppressants
               • Lifestyle modification
                              │
                    ┌─────────┴──────────┐
                    │                    │
               CONTROLLED           REFRACTORY
               (Continue)           (≥6 months)
                                         │
                              ↓
               STEP 2: INTRATYMPANIC THERAPY
               • IT Dexamethasone (if serviceable hearing)
               • IT Gentamicin (vertigo-dominant, poor hearing)
                    │
           ┌────────┴────────┐
           │                 │
      CONTROLLED          FAILED
      (Continue)               │
                               ↓
               STEP 3: SURGICAL OPTIONS
               ┌──────────────────────────────┐
               │                              │
        HEARING-PRESERVING            ABLATIVE SURGERY
        • Endolymphatic sac            • Labyrinthectomy
          decompression                  (no serviceable hearing)
        • Vestibular neurectomy        • Translabyrinthine
          (retrosigmoid / middle         approach
          fossa)

IT Gentamicin vs. Other Modalities

---

11. RECENT ADVANCES (Post-2015)

11A. Novel Drug Delivery Systems

• Thermosensitive hydrogels (poloxamer 407, chitosan-based): liquid at room temperature, gel in the middle ear → prolonged RWM contact, sustained release
• Nanoparticle-encapsulated gentamicin: liposomal and PLGA nanoparticles for controlled, targeted delivery
• Biodegradable microsphere systems: sustained release over days–weeks without repeated injections
• OTO-104 (sustained-release dexamethasone) has prompted similar sustained-release gentamicin formulation research

11B. Precision Dosing / Titration Endpoints

• Move toward objective audiometric titration rather than symptomatic endpoints
• Use of cervical VEMP (cVEMP) and ocular VEMP (oVEMP) as titration endpoint markers — monitors saccule/utricle function to guide dosing and stop before excessive toxicity
• Video Head Impulse Test (vHIT) as a real-time monitoring tool of semicircular canal function during titration

11C. Endolymphatic Hydrops Imaging

• Intratympanic gadolinium MRI (IT-Gd MRI) — 3D-FLAIR sequences 24 hours after IT gadolinium injection — allows direct visualization and grading of endolymphatic hydrops
• Can guide patient selection and assess treatment response
• Research role: correlating degree of hydrops with response to IT gentamicin

11D. Genetic Screening Before Treatment

• Screening for mitochondrial 12S rRNA A1555G mutation (mt.1555A>G) before IT gentamicin to identify patients at very high risk of profound HL
• May become standard pre-treatment workup

11E. Round Window Microcatheter Systems

• Continuous low-dose infusion (1 µL/hour) via implantable microcatheter
• Hoffer protocol: 10 mg/mL × 10 days — predictable pharmacokinetics, very low HL rate (1/36 patients)
• Major limitation: cost, surgical placement required

11F. Bilateral Ménière's Disease

• IT gentamicin in bilateral disease remains highly controversial
• Sequential bilateral treatment under careful monitoring with vHIT/VEMP is under investigation
• Bilateral vestibular loss leads to oscillopsia and severe dysequilibrium — major quality of life impact
• Cochlear implantation as rescue for profound bilateral HL post-gentamicin is now an established option

11G. Positive Predictive Factors (Research)

• Low pre-treatment caloric response predicts greater vestibular ablation
• Single-shot protocols showing comparable control to multi-shot in some RCTs (reduced HL)
• AAO-HNS guideline update (2020): IT gentamicin is now considered a second-line intervention after failure of IT steroids or medical therapy

---

12. COMPARISON OF TEXTBOOK PERSPECTIVES

---

13. SUMMARY FLOWCHART — IT GENTAMICIN DECISION & MONITORING

┌────────────────────────────────────────────────────────────┐
│         INTRATYMPANIC GENTAMICIN — COMPLETE PATHWAY        │
└────────────────────────────────────────────────────────────┘
                              │
              ┌───────────────┼───────────────┐
              ↓               ↓               ↓
         INDICATION      WORKUP           CONSENT
         Intractable     • Audiogram      • Hearing loss risk
         Ménière's       • Caloric test   • Disequilibrium
         Unilateral      • vHIT/VEMP      • Chemical
         Vertigo-        • MRI brain      labyrinthine upset
         dominant        • Genetic
                           screening
                              │
                              ↓
                     PROTOCOL CHOICE
              ┌───────────────┼───────────────┐
              ↓               ↓               ↓
         FIXED/SHOTGUN   TITRATION      SUSTAINED
         (high ablation) (preferred)   RELEASE
                              │
                              ↓
                     INJECT: 0.4–0.5 mL
                     Gentamicin 40 mg/mL
                     (pH buffered to 6.4–7.4)
                     Postero-inferior TM
                     Patient positioning ×30 min
                              │
                              ↓
                      MONITORING (weekly)
               ┌──────────────┬──────────────┐
               ↓              ↓              ↓
           AUDIOGRAM       VESTIBULAR      VERTIGO
           (PTA, SDS)      FUNCTION        DIARY
                           (caloric,
                            vHIT, VEMP)
                              │
              ┌───────────────┼────────────────┐
              ↓               ↓                ↓
         VERTIGO         SIGNIFICANT          NO
         CONTROLLED      HEARING LOSS         RESPONSE
              │          (STOP)               │
         OBSERVE &                        Repeat injection
         Rehab                            (up to 4 total)
                                               │
                                          Still no response
                                               ↓
                                     SURGICAL OPTIONS
                                   (Neurectomy/Labyrinthectomy)

---

14. IMPORTANT EXAM POINTS (RGUHS 50-Mark Focus)

1. Definition & principle: IT gentamicin = chemical ablation/subablation of the diseased labyrinth via transtympanic delivery to achieve vertigo control in intractable Ménière's disease
2. Mechanism: Preferential Type I hair cell damage + dark cell ionic disruption → reduces abnormal hydrops-induced impulses → vestibular compensation
3. Route: Tympanic membrane → middle ear → RWM → perilymph → inner ear (Type I > Type II vestibular hair cells damaged; cochlear cells relatively spared at low doses)
4. Drug concentration: 26.7–40 mg/mL (buffered with NaHCO₃ to pH 6.4–7.4)
5. Protocols: Fixed (shotgun — 4 consecutive days), Titration (weekly × 2–4), Sustained release (microcatheter/hydrogel)
6. Outcome criteria: AAO-HNS 1995 — Class A (complete control) to F
7. Complications: HL (0–30%), acute vestibular deafferentation, TM perforation, permanent disequilibrium, visual-vestibular mismatch
8. Contraindications: Only-hearing ear, contralateral vestibular deficit, mt.A1555G mutation, bilateral vestibular disease
9. Advantage over surgery: Outpatient, minimally invasive, repeatable, hearing-preserving potential, lower morbidity
10. Recent advances: vHIT/VEMP titration endpoints, IT-Gd MRI, thermosensitive hydrogels, nanoparticle delivery, genetic screening

---

• Cummings Otolaryngology Head and Neck Surgery, 7th Ed., Chapter 158 (IT Steroids & Gentamicin) & Chapter 167 (Ménière's Disease)
• KJ Lee's Essential Otolaryngology, 11th Ed.
• Scott Brown's Otolaryngology, 8th Ed.
• Dhingra — Diseases of ENT, Head & Neck
• Hazarika — Textbook of ENT Head & Neck Surgery
• Nedzelski JM et al. — Intratympanic gentamicin instillation, Laryngoscope 1992
• Hoffer ME et al. — Transtympanic vs. sustained-release gentamicin, Laryngoscope 111:1343, 2001
• AAO-HNS Committee on Hearing and Equilibrium guidelines, 1995